Voyager Therapeutics Inc Stock
€3.02
Your prediction
Voyager Therapeutics Inc Stock
Pros and Cons of Voyager Therapeutics Inc in the next few years
Pros
Cons
Performance of Voyager Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | 2.420% | 4.927% | 6.855% | -62.873% | -45.118% | -40.961% | -73.931% |
| Krystal Biotech | 0.620% | 5.076% | 3.196% | -26.248% | -20.434% | 137.451% | - |
| Ardelyx Inc. | 0.920% | -5.301% | 1.522% | -45.589% | -34.159% | 469.314% | -49.708% |
| Evolus Inc | 3.660% | 1.190% | -3.955% | -18.269% | -19.048% | -22.727% | 65.049% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Voyager (with US symbol VYGR) present a mixed bag of insights that highlight both challenges and resilience within the Biotechnology and Medical Research sector. A glance at the figures reveals a company that has been grappling with losses yet possesses assets and potential for recovery. The financial statements showcase an evolving narrative where investment in research and development is crucial for future growth, albeit at the expense of current profitability.
Starting with the positives, Voyager's balance sheet reflects a robust asset base, with total assets amounting to approximately $351.3 million as of December 31, 2023. This figure indicates that the company has a solid foundation on which to build future growth. Moreover, it maintains a healthy net working capital of about $255.2 million, suggesting that it can comfortably meet its short-term obligations, which reassures stakeholders regarding operational liquidity.
The cash flow statement for 2023 shows that Voyager generated $77.9 million from operating activities, ultimately leading to a positive free cash flow of about $74.7 million for the year. This cash flow capability could be attractive to investors, indicating that the company is still generating substantial cash, which is essential for funding research initiatives and sustaining operations despite the reported net losses.
News
How Much Does It Cost to Build a Space Station? Would You Believe Less Than $4 Billion?
It took 13 years, 15 nations, and roughly $100 billion to build the International Space Station (ISS). But one company thinks it can build a replacement for as little as $3 billion -- or less.
That
